Twelve‑month rehospitalization after IBD‑related hospitalization in Germany: A retrospective cohort study using administrative hospital data
Open Access
- 31 March 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0346270
Abstract
Background/Aims: Rehospitalization is an important indicator of disease burden and healthcare utilization in inflammatory bowel disease (IBD), yet real-world data from Germany remain scarce. This study aimed to describe 12‑month rehospitalization rates after IBD‑related inpatient treatment in Germany and to identify administrative and clinical factors recorded in hospital ICD‑10 coding that are associated with rehospitalization. Methods: In this multicenter retrospective cohort study, anonymized administrative data from 49 German hospitals (Section 21 dataset, 2019–2023) were analyzed. Patients hospitalized with a primary diagnosis of Crohn’s disease (ICD-10 K50) or ulcerative colitis (ICD-10 K51) were included. The primary endpoint was any rehospitalization within 12 months after the index admission. Univariable and multivariable logistic regression models were used to determine factors of rehospitalization. Results: A total of 3,202 patients were included (51.3% Crohn’s disease, 48.7% ulcerative colitis; mean age 44.2 years; 50.1% female). The 12-month rehospitalization rate was 22.6%, with a median time of 92 days (IQR 61–184). Independent factors in adjusted analyses were admission to a surgical department (AOR 1.79), peritoneal adhesions (AOR 1.98), type 2 diabetes mellitus (AOR 1.54), and hypokalemia (AOR 1.30). Age, sex, and IBD subtype showed no association. Conclusion: Using administrative hospital data, we identified several ICD-10–coded comorbidities and treatment characteristics associated with higher rehospitalization rates. These findings highlight subgroups that may benefit from improved post-discharge management, although clinical interpretation is limited by the administrative nature of the dataset.Keywords
This publication has 19 references indexed in Scilit:
- The Cost of Inflammatory Bowel Disease Care: How to Make it SustainableClinical Gastroenterology and Hepatology, 2024
- Impact of malnutrition and sarcopenia on quality of life in patients with inflammatory bowel disease: A multicentre studyJournal of Cachexia, Sarcopenia and Muscle, 2023
- The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology CommissionThe Lancet Gastroenterology & Hepatology, 2023
- P416 The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United KingdomJournal of Crohn's and Colitis, 2023
- Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2020
- The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Gastroenterology & Hepatology, 2020
- Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2019
- Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2018
- Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver DiseasesClinical Gastroenterology and Hepatology, 2018
- Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide DatabaseInflammatory Bowel Diseases, 2017